Eutropics' PRIMABS™-Dx: Functional Predictive Biomarkers for Precision Medicine
Eutropics’ PRIMABS-Dx platform translates mitochondrial priming biology into scalable, multiplexed, companion diagnostics that de-risk oncology pipelines to guide precision patient treatment.
The Clinical Problem: Failure to Match Therapy to Tumor Biology
Current Gap in Oncology
In AML and other hematologic malignancies, no universally accepted predictive biomarkers exist for venetoclax or many targeted therapy combinations. This uncertainty drives suboptimal treatment decisions, delays response assessment, and increases healthcare costs while patients progress on ineffective regimens.
- Genomic markers alone fail to predict functional drug response
- Traditional protein assays miss critical mitochondrial dynamics
- No scalable functional companion diagnostics available
The Challenge
40–60% of cancer patients fail first-line therapy with otherwise effective drugs, often without clear mechanistic explanation.
Functional alterations in cancer cells need toi be considered in the administering of targeted immune and chemo therapies.
These considerations must be linked to the mechanistic features of drugs used at time of diagnosis and during the course of treatment
First in Class Functional CDx
Our technology delivers clinical biomarkers built on mechanistic cell-death pathways defined by BCL-2 family protein-protein interactions. The PRIMABS-Dx platform .uniquely reads out the final common pathway of many cancer drugs—mitochondrial priming —rather than simply relying on upstream genetics.
Importantly this priming is downstream of the known genetic mutations meaning that with or without the known mutations mitochondrial priming will impact patient response.
Overcomes limitations of existing cellular response assays
Specifically, we quantify how BH3 mimetics, like venetoclax, disrupt anti-apoptotic PPIs to unleash cell death, providing direct insights into drug response at a functional level.